History of Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis was a condition that puzzled neurologists for much of the nineteenth and twentieth centuries, as physicians struggled to understand the progressive destruction of motor neurons they observed in affected patients. The disease gained widespread public attention in the 1930s when it was diagnosed in the celebrated American baseball player Lou Gehrig, lending it an informal name that persisted in popular culture for decades. Historical investigations into the condition laid important groundwork for the broader field of neurodegenerative disease research.

Historical Narrative

The earliest systematic clinical descriptions of what would come to be called amyotrophic lateral sclerosis emerged in the mid-nineteenth century from French neurology, a discipline then experiencing a remarkable period of institutional growth centered on the Salpêtrière hospital in Paris. The French neurologist Jean-Martin Charcot is credited with providing the first comprehensive clinical and pathological account of the disease, which he presented in a series of lectures between 1869 and 1874. Charcot and his colleague Alexis Joffroy examined post-mortem tissue from patients who had experienced progressive muscular wasting combined with signs of spasticity, and they identified characteristic sclerotic changes in the lateral columns of the spinal cord alongside degeneration of anterior horn cells. Charcot coined the term amyotrophic lateral sclerosis to capture these dual pathological features, with amyotrophic referring to muscle wasting and lateral sclerosis describing the hardening observed in the spinal cord's lateral tracts. Prior to Charcot's consolidating work, earlier physicians had described overlapping clinical pictures without fully distinguishing them from one another. The Scottish physician Charles Bell had done foundational work in the 1820s on the anatomy of the spinal cord and motor nerves, and his framework for understanding motor function provided later researchers with essential conceptual tools. François Amilcar Aran had described progressive muscular atrophy in 1850, and Guillaume Duchenne de Boulogne had written on progressive bulbar palsy, both conditions that physicians of the era sometimes conflated with what Charcot would later delineate more precisely. Throughout the late nineteenth century, neurologists debated where the primary site of pathology resided, with some emphasizing the spinal cord's anterior horns and others pointing to the lateral columns, and Charcot's contribution was largely in insisting that both sites were simultaneously and characteristically affected. In the early twentieth century, interest in the condition grew as neuropathological techniques improved and as clinicians in Europe and North America accumulated larger case series. The diagnosis of Lou Gehrig in 1939 brought the disease to public consciousness in the United States in a way that purely academic publications never had, and charitable and research organizations began forming in subsequent decades partly as a result of that cultural moment. Researchers in the mid-twentieth century began examining whether geographic clusters of the disease, particularly the unusually high prevalence observed among the Chamorro people of Guam during the 1940s and 1950s, might offer clues to underlying causes. Studies by Leonard Kurland and Donald Mulder at the National Institutes of Health investigated this Guamanian cluster extensively, and their work prompted hypotheses about environmental and nutritional factors, including the possible role of a neurotoxic amino acid found in cycad seeds consumed in the local diet. The discovery in 1993 by a research team that included Robert Brown that mutations in the gene encoding the enzyme superoxide dismutase 1 were associated with familial forms of the disease represented a landmark molecular turning point, shifting scientific understanding toward genetic and biochemical frameworks that had been largely absent from earlier centuries of inquiry. Across roughly 150 years of organized investigation, the condition moved from a clinically described curiosity in a Parisian hospital to a subject of international genetic and neurochemical research.

Key Historical Figures

• Jean-Martin Charcot
• Alexis Joffroy
• Charles Bell
• François Amilcar Aran
• Guillaume Duchenne de Boulogne
• Leonard Kurland
• Donald Mulder
• Robert Brown

Historical narrative only — this page describes how Amyotrophic lateral sclerosis was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.